Immune thrombocytopenic purpura after recombinant hepatitis B vaccine

Basit Öğe Kaydı
dc.contributor.authorIncecik, Faruk
dc.contributor.authorOenlen, Yusuf
dc.contributor.authorOezcan, Kenan
dc.date.accessioned2024-09-18T20:08:14Z
dc.date.available2024-09-18T20:08:14Z
dc.date.issued2007
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractRecombinant hepatitis B vaccine, which is used throughout the world, rarely has systemic adverse events like polyradiculoneuritis, demyelination of central nervous system. otoimmune hemolytic anemia and immune thrombocytopenia, as well as local side effects. We diagnosed thrombocytopenic purpura in a 10 months-old case, which developed 3 weeks after the 3(rd) dose of the recombinant hepatitis B vaccine. There was no drug history or prior infection. Clinical and laboratory findings of autoimmune or malignant disorders were negative and the bone marrow aspirate was normal. We presented this case to emphasize that thrombocytopenia may develop after recombinant hepatitis B vaccine and thus Should be taken into consideration.en_US
dc.identifier.endpage799en_US
dc.identifier.issn1300-0292
dc.identifier.issue5en_US
dc.identifier.startpage797en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12483/8729
dc.identifier.volume27en_US
dc.identifier.wosWOS:000254582800025en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isotren_US
dc.publisherOrtadogu Ad Pres & Publ Coen_US
dc.relation.ispartofTurkiye Klinikleri Tip Bilimleri Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectchickenpoxen_US
dc.subjectpurpuraen_US
dc.subjectthrombocytopenicen_US
dc.subjectidiopathicen_US
dc.titleImmune thrombocytopenic purpura after recombinant hepatitis B vaccineen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu